NOVN Novan Inc.

1.28
-0.12  -9%
Previous Close 1.4
Open 1.38
Price To Book -14.21
Market Cap 33329170
Shares 26,056,735
Volume 138,325
Short Ratio
Av. Daily Volume 59,303

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 181191363
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181158756
  3. 8-K - Current report 181112217
  4. 8-K - Current report 181058929
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999894

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 trial to be initiated 1H 2019 with data due late 2019 or early 2020.
SB206
Molluscum contagiosum skin infection
Phase 1b trial completion announced August 20, 2018.
SB414
Atopic Dermatitis

Latest News

  1. Novan Announces Top-Line Data From Mid-Stage Molluscum Study
  2. Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
  3. Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
  4. Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?
  5. Novan to Present at Piper Jaffray 30th Annual Healthcare Conference
  6. Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
  7. Consolidated Research: 2018 Summary Expectations for Moleculin Biotech, Novan, PAVmed, Maui Land & Pineapple, Hallmark Financial Services, and McEwen Mining — Fundamental Analysis, Key Performance Indications
  8. Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
  9. Novan (NOVN) Reports Q3 Loss, Lags Revenue Estimates
  10. Novan Announces Corporate Update Conference Call and Webcast
  11. The most valuable public companies in the Triangle (Slideshow)
  12. Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
  13. Novan Creates Dedicated Women’s Health Business Unit
  14. Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation
  15. Novan scores $11M with partnership with Japanese pharma
  16. Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
  17. Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
  18. Novan Sees Hammer Chart Pattern: Time to Buy?
  19. Before You Buy Novan Inc’s (NASDAQ:NOVN), Consider This
  20. The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering